Akar, ServetKalyoncu, UmutDalkılıç, EdizEmmüngil, HakanAziz, AytenEsen, YaseminKoç, Tuba2024-06-252024-06-252021-04-211750-743Xhttps://doi.org/10.2217/imt-2020-0296https://www.tandfonline.com/doi/full/10.2217/imt-2020-0296https://hdl.handle.net/11452/42317Aim: To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Materials & methods: Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Patients were classified as biologic-naive and biologic-experienced. Results: The study included 60 RA and 269 ax-SpA patients. At month 24, the retention rates were 67.2 and 57.1% (biologic-naive and biologic-experienced RA) and 74.8 and 80.4% (anti-TNF-naive and -experienced ax-SpA). No significant differences in retention were observed between the biologic-naive and -experienced groups for either disease. Conclusion: The results of this study confirm the effectiveness of GLM in the treatment of RA and axSpA with good retention rates at 2 years in a real-world setting in Turkey.eninfo:eu-repo/semantics/closedAccessAxial spondyloarthritisBiologicEfficacyGolimumabRetentionRheumatoid arthritisTNF-αInhibitorImmunologyArticle000647582000001841850131010.2217/imt-2020-02961750-7448